Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Eden vs PepHaūs

Both scored on the same six-factor Match Score. Eden wins this matchup with a 87 to 64 edge.

Higher Match Score

Eden

#7 · Grade B+

People who prioritize a vetted, high-transparency, high-touch provider over the lowest sticker price.

Visit Eden
VS

PepHaūs

#228 · Grade C

Shoppers who want all-inclusive compounded GLP-1 pricing shipped nationwide.

Visit PepHaūs

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
74
32
Speed to Start
90
90
Formulary Match
80
72
Support Level
94
78
Flexibility
90
20
Transparency
92
94

Price, coverage & formulary

DetailEdenPepHaūs
Semaglutide$239/mo$152/mo (quarterly plan, compounded)
Tirzepatide$349/mo$246/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjectable onlyInjectable only
Match Score87 · B+64 · C
Winner: Eden

Eden edges out PepHaūs, 87 to 64 on the default Match Score. A polished, high-disclosure compounded program with strong nationwide coverage and hands-on support.

PepHaūs is still a fair pick if its strengths line up with yours — best for: Shoppers who want all-inclusive compounded GLP-1 pricing shipped nationwide.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Eden reviewFull PepHaūs review

More head-to-heads

Or browse alternatives to Eden and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.